Table 4.
Concordance between CTC positivity evaluated by AdnaTest (AT) and Screen Cell (SC) on the same samples and as a function of the line of treatment.
| Clinical setting | Before therapy | After therapy | ||||||
|---|---|---|---|---|---|---|---|---|
| N | CTC+ by AT (%) | CTC+ by SC (%) | Concordant samples (%) | N | CTC+ by AT (%) | CTC+ by SC (%) | Concordant samples (%) | |
| M0 | 13 | 4 (30.8) | 11 (84.6) | 4 (30.8%) | 10 | 5 (50.0) | 4 (40.0) | 3 (30.0%) |
| M1 | 27 | 16 (59.3) | 22 (81.5) | 15 (55.6%) | 21 | 17 (81.0) | 19 (90.5) | 15 (71.4%) |
| M2 | 11 | 8 (72.7) | 10 (90.9) | 7 (63.6%) | 8 | 8 (100.0) | 7 (87.5) | 7 (87.5%) |
| Total | 51 | 28 (54.9) | 43 (84.3) | 26 (50.9%) | 39 | 30 (76.9) | 30 (76.9) | 25 (64.1%) |